Evidence map›Paper›PMID 41721360›Full record

ArticleBMC research notes2026

Association between non-high-density lipoprotein cholesterol and non-alcoholic fatty liver disease among people living with HIV on dolutegravir-based antiretroviral therapy: A cross-sectional study in Southwestern Uganda.

Charles Nkubi Bagenda, Carol Nantongo, Elastus Ssemwanga, Michael Junior Mugisa, Jesca Wafwoyo Akoth, Daniel Nzaramba, Rogers Kalyetsi, Elizabeth A John, Jazira Tumusiime, Blendar Ainebyoona and 11 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC research notes, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Charles Nkubi BagendaDepartment of Medical Laboratory Science, Faculty of Medicine, Mbarara University of Science and Technology, P.O. Box 1410, Mbarara, Uganda. cbagenda@must.ac.ug.
Carol NantongoDepartment of Medical Laboratory Science, Uganda Institute of Allied Health and Management Sciences, P.O. Box, 34025, Kampala, Uganda.
Elastus SsemwangaDepartment of Medical Laboratory Technology, Mayanja Memorial Medical Training Institute, P.O Box 348, Mbarara, Uganda.
Michael Junior MugisaDepartment of Medical Laboratory Science, Faculty of Medicine, Mbarara University of Science and Technology, P.O. Box 1410, Mbarara, Uganda.
Jesca Wafwoyo AkothDepartment of Medical Laboratory Science, Faculty of Medicine, Mbarara University of Science and Technology, P.O. Box 1410, Mbarara, Uganda.
Daniel NzarambaDepartment of Medical Laboratory Science, Faculty of Medicine, Mbarara University of Science and Technology, P.O. Box 1410, Mbarara, Uganda.
Rogers KalyetsiDepartment of Medical Laboratory Science, Faculty of Medicine, Mbarara University of Science and Technology, P.O. Box 1410, Mbarara, Uganda.
Elizabeth A JohnDepartment of Microbiology and Parasitology, School of Medicine and Dentistry, P.O. Box 259, Dodoma, Tanzania.
Jazira TumusiimeDepartment of Medical Laboratory Science, Faculty of Medicine, Mbarara University of Science and Technology, P.O. Box 1410, Mbarara, Uganda.
Blendar AinebyoonaDepartment of Medical Laboratory Science, Uganda Institute of Allied Health and Management Sciences, P.O. Box, 34025, Kampala, Uganda.
Shadrach OmaraDepartment of Medical Laboratory Science, Faculty of Medicine, Mbarara University of Science and Technology, P.O. Box 1410, Mbarara, Uganda.
Vicent MwesigyeDepartment of Medical Laboratory Science, Faculty of Medicine, Mbarara University of Science and Technology, P.O. Box 1410, Mbarara, Uganda.
Sylvia Achieng LumumbaDepartment of Medical Laboratory Sciences, School of Medicine, Technical University of Mombasa, P.O. Box 90420, Mombasa, Kenya.
Conrad LubwamaDepartment of Physiology, Faculty of Health Science, Mountains of the moon University, P.O Box 837, Fort Portal, Uganda.
Benson MusinguziDepartment of Medical Laboratory Sciences, Faculty of Medicine, Muni University, P.O. Box, 725, Arua, Uganda.
Lucas AmpaireDepartment of Medical Laboratory Science, Faculty of Medicine, Mbarara University of Science and Technology, P.O. Box 1410, Mbarara, Uganda.
Rose NassaliDepartment of Medical Laboratory Science, Uganda Institute of Allied Health and Management Sciences, P.O. Box, 34025, Kampala, Uganda.
Herbert ItabangiDepartment of Microbiology and Immunology, Faculty of Health Sciences, Busitema University, P.O Box 1460, Mbale, Uganda.
Lawrence Obado OsuwatDepartment of Medical Laboratory Science, School of Health Sciences, Soroti University, P.O. Box 211, Soroti, Uganda.
Brian SsenkumbaDepartment of Pathology, Faculty of Health Sciences, Busitema University, P.O Box 1460, Mbale, Uganda.
Ronald Ouma OmoloDepartment of Physiology, Faculty of Medicine, Mbarara University of Science and Technology, P.O. Box 1410, Mbarara, Uganda.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveNon-high-density lipoprotein cholesterol, an aggregate marker of atherogenic lipoproteins, has been implicated in metabolic dysfunction and may predict non-alcoholic fatty liver disease risk. Our study investigated the association between non-high-density lipoprotein cholesterol and non-alcoholic fatty liver disease among people living with Human Immunodeficiency Virus on dolutegravir-based antiretroviral therapy in southwestern Uganda. We conducted a secondary analysis of data obtained from a cross-sectional study of 377 adults who had been on dolutegravir-based antiretroviral therapy for ≥ 12 months at Ruhoko Health Centre IV, southwestern Uganda.

resultsOf the 377 participants, 42(11.1%; 95CI: 8.3–14.8) had non-alcoholic fatty liver disease. We observed a significant association between high non-high-density lipoprotein cholesterol and non-alcoholic fatty liver disease; second tertile (aOR = 3.08, 95% CI: 1.06–8.99, p = 0.039) and third tertile (aOR = 4.46, 95% CI: 1.25–15.88, p = 0.021). At an optimal cut-off of ≥ 113.4 with a sensitivity of 69% and specificity of 48%, non-high-density lipoprotein cholesterol had a significant discriminative ability; AUC = 0.654(95%CI:0.561–0.747) to distinguish participants with from those without non-alcoholic fatty liver disease. Therefore, High non-high-density lipoprotein cholesterol is a potential predictor for non-alcoholic fatty liver disease.

Indexed as

Heterocyclic Compounds, 3-RingHIV InfectionsNon-alcoholic Fatty Liver DiseaseAdultCross-Sectional StudiesDolutegravirFemaleHumansMaleMiddle AgedOxazinesPiperazinesPyridonesUgandaDolutegravirHeterocyclic Compounds, 3-RingOxazinesPiperazinesPyridonesAtherogenic lipidFatty liver indexNon-alcoholic fatty liver disease

Identifiers

PMID41721360
PMCPMC13032707

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.